Related Experiment Video

Updated: Apr 30, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

2.2K

HIV/hepatitis C virus coinfection management: changing guidelines and changing paradigms

C L Cooper1, M B Klein

  • 1Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.

HIV Medicine
|May 8, 2014
PubMed

Insights

New direct-acting antiviral (DAA) regimens offer a paradigm shift in treating hepatitis C virus (HCV) in patients with HIV/HCV coinfection. These improved therapies can be safely administered to nearly all patients, improving individual outcomes and public health.

Area of Science:

  • Infectious Diseases
  • Hepatology
  • Virology

Background:

  • Hepatitis C virus (HCV) coinfection in patients with HIV presents unique treatment challenges.
  • Current guidelines recommend prioritizing HIV antiretroviral therapy before initiating HCV treatment.

Purpose of the Study:

  • To evaluate the impact of new direct-acting antiviral (DAA) regimens on HCV treatment strategies for individuals with HIV/HCV coinfection.
  • To assess how advancements in DAAs alter current treatment paradigms.

Main Methods:

  • Review of current coinfection guidelines.
  • Analysis of recent DAA publications focusing on HIV-coinfected populations.

Main Results:

  • New all-oral DAA regimens are better tolerated, allowing for broader application in coinfected patients.
  • These regimens can be safely offered to nearly all patients with HIV/HCV coinfection.
  • All-oral DAAs may reduce HCV incidence by enabling safe and widespread treatment in high-risk populations.

Conclusions:

  • HCV treatment should no longer be a secondary consideration for HIV/HCV-coinfected patients.
  • The advent of new DAAs necessitates a revision of treatment prioritization in coinfected individuals.
Abstract

Keywords:
HIVcoinfectionguidelineshepatitis C virusparadigm

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

20.3K
A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

23.7K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
43.0K
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
25
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
657
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
58
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
4.7K